Initial results from an ECOG-ACRIN and Caris Life Sciences collaboration show AI-driven multimodal models can more accurately predict recurrence risk in early-stage breast cancer.
Key Details
- 1Collaboration leverages ECOG-ACRIN's clinical trial data and Caris' molecular profiling and imaging AI platforms.
- 2Over 4,000 TAILORx trial patient cases used to train and validate new multimodal deep learning models.
- 3Models integrate histopathologic slide imaging, clinical, and expanded gene expression data.
- 4AI models outperformed established recurrence risk assessment methods, especially for late recurrence (after 5 years).
- 5Potential shown for a scalable, cost-effective diagnostic test based on routine histology and clinical data rather than solely on genomic assays.
- 6Results presented at the 2023 San Antonio Breast Cancer Symposium.
Why It Matters
The study demonstrates unprecedented large-scale integration of imaging, molecular, and clinical data for recurrence prognostication, charting a path toward more personalized and precise breast cancer management. Imaging AI's role in such multimodal frameworks signifies a promising advance for the development of new diagnostic tools in oncologic pathology.
Source
EurekAlert
Related News
•EurekAlert
UVA's $4M NIH Grant Backs AI to Optimize Cardiac MRI Therapies
UVA secures $4 million NIH funding to develop GenStrain, an AI model using MRI data to personalize cardiac pacing therapies.
•EurekAlert
Machine Learning Models Predict Cancer Risk with Routine Health Data
Researchers developed machine learning models using routinely collected health data to predict individual risk for 20 common cancers, outperforming traditional methods for several cancer types.
•EurekAlert
Duke Receives $25M to Lead National Trustworthy AI Hub for Dementia and Aging
Duke University has launched a $25 million national center to make AI for aging and dementia clinically robust and trustworthy.